<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1382">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04517188</url>
  </required_header>
  <id_info>
    <org_study_id>HDN-N02-COV24A</org_study_id>
    <nct_id>NCT04517188</nct_id>
  </id_info>
  <brief_title>Halodine Nasal Antiseptic in Patients With COVID-19</brief_title>
  <official_title>A Phase 4 Study to Evaluate Nasopharyngeal SARS-CoV-2 Viral Shedding After Halodine Nasal Antiseptic in Patients With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Halodine LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Halodine LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Povidone iodine (PVP-I) is a well-known broad spectrum, resistance free antimicrobial agent
      that has a long history of safe and effective use. Halodine Nasal Antiseptic is formulated
      for topical application PVP-I to nasal passages, and has demonstrated effectiveness against
      SARS-COV-2 in vitro - 99.99% inactivation within 15 seconds. This study will evaluate the
      ability of Halodine Nasal Antiseptic to impact SARS-CoV-2 in vivo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, phase 4 prospective, single-cohort study in adult male and female
      volunteers hospitalized with COVID-19. Baseline nasopharyngeal swabs will be performed on all
      individuals. Halodine Nasal Antiseptic will then be applied to the anterior nares. Serial
      nasopharyngeal samples will then be collected at specified time points after the application.
      All samples will be tested for SARS-CoV-2 by real-time reverse transcription (rRT)-PCR assay.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 15, 2020</start_date>
  <completion_date type="Anticipated">February 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 15, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nasopharyngeal SARS-CoV-2 Viral Load</measure>
    <time_frame>4 hours</time_frame>
    <description>Real-time reverse transcription (rRT)-PCR assay for SARS-CoV-2</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>SARS-CoV-2 Infection</condition>
  <arm_group>
    <arm_group_label>Halodine Nasal Antiseptic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Povidone-Iodine Solution 1.25% w/w [0.125% available iodine] USP
Single topical administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Povidone-Iodine Solution 1.25% w/w [0.125% available iodine] USP</intervention_name>
    <description>Single topical administration</description>
    <arm_group_label>Halodine Nasal Antiseptic</arm_group_label>
    <other_name>Halodine Nasal Antiseptic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hospitalized with COVID-19

          -  Positive SARS-CoV-2 (rRT)-PCR within 48 hours of enrollment

        Exclusion Criteria:

          -  Allergies to iodine-containing compounds
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel Barone, MD</last_name>
    <role>Study Director</role>
    <affiliation>Halodine LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Samuel B Barone, MD</last_name>
    <phone>2023908590</phone>
    <email>sbarone@halodine.com</email>
  </overall_contact>
  <link>
    <url>https://halodine.com/science/</url>
    <description>Sponsor's Science Website</description>
  </link>
  <reference>
    <citation>Bidra AS, Pelletier JS, Westover JB, Frank S, Brown SM, Tessema B. Rapid In-Vitro Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Using Povidone-Iodine Oral Antiseptic Rinse. J Prosthodont. 2020 Jul;29(6):529-533. doi: 10.1111/jopr.13209. Epub 2020 Jun 16.</citation>
    <PMID>32511851</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 15, 2020</study_first_submitted>
  <study_first_submitted_qc>August 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2020</study_first_posted>
  <last_update_submitted>September 2, 2020</last_update_submitted>
  <last_update_submitted_qc>September 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nasopharyngeal SARS-CoV-2 Viral Load</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iodine</mesh_term>
    <mesh_term>Povidone-Iodine</mesh_term>
    <mesh_term>Povidone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

